Apremilast for discoid lupus erythematosus: results of a phase 2, open-label, single-arm, pilot study.
A De Souza, BE Strober, JF Merola… - Journal of drugs in …, 2012 - europepmc.org
A De Souza, BE Strober, JF Merola, S Oliver, AG Franks Jr
Journal of drugs in dermatology: JDD, 2012•europepmc.orgBackground Discoid lupus erythematosus (DLE) is a chronic inflammatory disorder
mediated by Th1 cells. Apremilast is a novel oral PDE4 enzyme inhibitor capable of blocking
leukocyte production of IL-12, IL-23, TNF-a, INF-with subsequent suppression of Th1 and
Th17-mediated immune responses, and proven clinical efficacy for psoriasis as well as
rheumatoid and psoriatic arthritis.
mediated by Th1 cells. Apremilast is a novel oral PDE4 enzyme inhibitor capable of blocking
leukocyte production of IL-12, IL-23, TNF-a, INF-with subsequent suppression of Th1 and
Th17-mediated immune responses, and proven clinical efficacy for psoriasis as well as
rheumatoid and psoriatic arthritis.
Background
Discoid lupus erythematosus (DLE) is a chronic inflammatory disorder mediated by Th1 cells. Apremilast is a novel oral PDE4 enzyme inhibitor capable of blocking leukocyte production of IL-12, IL-23, TNF-a, INF-with subsequent suppression of Th1 and Th17-mediated immune responses, and proven clinical efficacy for psoriasis as well as rheumatoid and psoriatic arthritis.
europepmc.org
以上显示的是最相近的搜索结果。 查看全部搜索结果